J. Lynn Fink

Dr. J. Lynn Fink


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2016 in Nature
Verified
Journal Article
Closed access
PDF file
PBPeter Bailey
Peter Bailey
DCDavid K. Chang
David K. Chang
Katia NonesKatia Nones
Katia Nones
AJAmber L. Johns
Amber L. Johns
APAnn-Marie Patch
Ann-Marie Patch
SGSean M. Grimmond
Sean M. Grimmond

5 February 2020 in Nature
Verified
Journal Article
Open access
PDF file
Taobo HuTaobo Hu
Taobo Hu
LALauri A. Aaltonen
Lauri A. Aaltonen
FAFederico Abascal
Federico Abascal
AAAdam Abeshouse
Adam Abeshouse
HAHiroyuki Aburatani
Hiroyuki Aburatani
CMChristian von Mering
Christian von Mering
Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1–3. Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4–5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter4; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation5,6; analyses timings and patterns of tumour evolution7; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity8,9; and evaluates a range of more-specialized features of cancer genomes8,10–18.

25 February 2015 in Nature
Verified
Journal Article
Closed access
PDF file
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
Nic WaddellNic Waddell
Nic Waddell
MPMarina Pajic
Marina Pajic
APAnn-Marie Patch
Ann-Marie Patch
DCDavid K Chang
David K Chang
SGSean M. Grimmond
Sean M. Grimmond

24 October 2012 in Nature
Verified
Journal Article
Closed access
PDF file
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
ABAndrew V. Biankin
Andrew V. Biankin
Nic WaddellNic Waddell
Nic Waddell
KKKarin Kassahn
Karin Kassahn
MGMarie-Claude Gingras
Marie-Claude Gingras
SGSean M. Grimmond
Sean M. Grimmond

27 May 2015 in Nature
Verified
Journal Article
Closed access
PDF file
APAnn-Marie Patch
Ann-Marie Patch
ECElizabeth L Christie
Elizabeth L Christie
DEDariush Etemadmoghadam
Dariush Etemadmoghadam
DGDale W. Garsed
Dale W. Garsed
JGJoshy George
Joshy George
DBDavid D. L. Bowtell
David D. L. Bowtell

15 February 2017 in Nature
Verified
Journal Article
Closed access
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
ASAldo Scarpa
Aldo Scarpa
DCDavid K. Chang
David K. Chang
Katia NonesKatia Nones
Katia Nones
VCVincenzo Corbo
Vincenzo Corbo
SGSean M. Grimmond
Sean M. Grimmond